AB
Autoimmunity BioSolutions
United States · Biotech · Healthtech
Genetically guided therapies targeting elevated soluble IL7 receptor levels in autoimmune disease.
Targeting a genetically defined patient group
Autoimmunity BioSolutions develops investigational therapies intended to reduce elevated soluble IL7 receptor levels. Its approach targets a genetic variant associated with increased receptor expression and poorer responses to existing autoimmune treatments. The company is studying this mechanism in diseases including rheumatoid arthritis and lupus nephritis.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed extension | $1M | Elmstead Partners — Role not disclosedEos BioInnovation — Role not disclosedIndependent Capital — Role not disclosedNewTech Investment Holdings — Role not disclosed |